Personalised pharmacometabolomic optimisation of treatment for hypertension

Informations projet

Hypermarker

N° de convention de subvention: 101095480

DOI

10.3030/101095480

Date de signature de la CE 8 Decembre 2022

Date de début 1 Janvier 2023

Date de fin 31 Decembre 2026

Financé au titre de

• Health

Coût total

€ 8 046 250,00

Contribution de l’UE

€ 8 046 250,00

Coordonné par

UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Netherlands

Periodic Reporting for period 1 - Hypermarker (Personalised pharmacometabolomic optimisation of treatment for hypertension)

Période du rapport: 2023-01-01 au 2024-06-30

Résumé du contexte et des objectifs généraux du projet

Hypertension, a prevalent condition affecting millions worldwide, remains a significant public health challenge due to its complex and multifactorial nature. The HYPERMARKER project aims to address this challenge by leveraging pharmacometabolomics to personalize antihypertensive treatment. By identifying metabolic biomarkers associated with treatment response, the project seeks to optimize therapeutic strategies, thereby reducing the burden of uncontrolled hypertension.

The project operates within a broader context of increasing emphasis on precision medicine, where the integration of social sciences and humanities plays a crucial role in addressing the ethical, legal, and societal implications of using advanced AI-driven technologies in healthcare.

HYPERMARKER's objectives include the development of predictive models and clinical decision support tools, validated through randomized controlled trials, that will ultimately inform international hypertension guidelines. The project's pathway to impact is clear: by improving hypertension management, it aims to reduce morbidity and mortality associated with cardiovascular diseases, significantly impacting public health at both European and global levels.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

During the reporting period, HYPERMARKER has made significant progress in several key areas. The project successfully established a comprehensive governance and communication structure, facilitating collaboration across its multidisciplinary consortium. Technical achievements include the selection and shipment of samples from three large cohorts of patients and the initiation of data analysis to identify biomarkers predictive of antihypertensive treatment response.
The project also started developing an optimized metabolomics and exposomics platform, which will be critical for the ongoing and future analyses. Furthermore, efforts to integrate existing cohort data and harmonize these datasets have progressed, despite delays in accessing some data sources. The machine learning models for predicting treatment outcomes are in early development, with preliminary models already being tested using available data.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

After just 1.5 years this is too early to report. However, the integration of FAIR (Findable, Accessible, Interoperable, and Reusable) data principles will ensure that the project's findings are easily accessible and applicable in real-world settings.

project logo